Scolaris Content Display Scolaris Content Display

Cochrane Database of Systematic Reviews

Recombinant interferon beta or glatiramer acetate for delaying conversion of the first demyelinating event to multiple sclerosis

Esta versión no es la más reciente

ver la versión actual 23 abril 2008

Información

DOI:
https://doi.org/10.1002/14651858.CD005278.pub2Copiar DOI
Base de datos:
  1. Cochrane Database of Systematic Reviews
Versión publicada:
  1. 18 octubre 2006see what's new
Tipo:
  1. Intervention
Etapa:
  1. Protocol
Grupo Editorial Cochrane:

  1. Grupo Cochrane de Esclerosis múltiple y enfermedades raras del sistema nervioso central

Copyright:
  1. Copyright © 2008 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Cifras del artículo

Altmetric:

Citado por:

Citado 0 veces por enlace Crossref Cited-by

Contraer

Autores

  • Marinella Clerico

    Correspondencia a: Dipartimento di Neuroscienze, Università degli Studi di Torino‐ Ospedale S.Luigi Gonzaga, Orbassano, Italy

    [email protected]

  • Fabrizio Faggiano

    Dipartimento di Medicina Clinica e Sperimentale, Università degli Studi del Piemonte Orientale, Novara, Italy

  • Jacqueline A Palace

    Clinical Neurology, Radcliffe Infirmary Hospital, Oxford, UK

  • George PA Rice

    Clinical Neurological Sciences, University of Western Ontario, London, Canada

  • M Tintorè

    Other

  • Luca Durelli

    Dipartimento di Neuroscienze, Universita' degli Studi di Torino‐ Ospedale S. Luigi Gonzaga, Orbassano (TO), Italy

  • Mar Tintorè Subirana

    Val D'Hebòn Hospital, Barcelona, Spain

Contributions of authors

Dr. Durelli conceived the idea and with all the other reviewers designed the review and prepared the protocol.

Sources of support

Internal sources

  • No sources of support supplied

External sources

  • Associazione Firni, Italy.

  • Regione Piemonte, Italy.

Declarations of interest

Dr. Clerico hasn't conflict of interest to declare.
Prof. Faggiano hasn't conflict of interest to declare.
Dr. Palace has received financial support for multicentre clinical trials, running a National MS database, attending advisory committees, giving lectures, attending international meetings from TEVA, BIOGEN, SERONO and SHERING.
Prof Rice has participated in clinical trials sponsored by SCHERING, SERONO, BERLEX, BIOGEN, and TEVA. He has received honoraria from these companies.
Dr. Tintorè was an investigator in the ETOMS study and has received occasionally honoraria as faculty in scientific meetings and her group has received grants from the major interferon beta/glatiramer acetate drug companies.
Prof. Durelli served as steering committee member and as investigator of ETOMS trial; in addition he received consultant fees from SCHERING, SERONO, and BIOGEN.

Version history

Published

Title

Stage

Authors

Version

2008 Apr 23

Recombinant interferon beta or glatiramer acetate for delaying conversion of the first demyelinating event to multiple sclerosis

Review

Marinella Clerico, Fabrizio Faggiano, Jaqueline Palace, George PA Rice, Mar Tintorè Subirana, Luca Durelli

https://doi.org/10.1002/14651858.CD005278.pub3

2006 Oct 18

Recombinant interferon beta or glatiramer acetate for delaying conversion of the first demyelinating event to multiple sclerosis

Protocol

Marinella Clerico, Fabrizio Faggiano, Jacqueline A Palace, George PA Rice, M Tintorè, Luca Durelli, Mar Tintorè Subirana

https://doi.org/10.1002/14651858.CD005278.pub2

2005 Apr 20

Recombinant interferon beta or glatiramer acetate for delaying conversion of the first demyelinating event to multiple sclerosis

Protocol

Marinella Clerico, Fabrizio Faggiano, Jacqueline Palace, George PA Rice, M Tintorè, Luca Durelli, Mar Tintorè Subirana

https://doi.org/10.1002/14651858.CD005278

Keywords

MeSH

Medical Subject Headings (MeSH) Keywords

Medical Subject Headings Check Words

Humans;